Test Activity for JA-2752
Test Activity for JA-2752

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.
How would you manage Kendra's symptoms of fatigue after initiating lenvatinib plus pembrolizumab for her recurrent MSI-stable endometrial cancer?
2.

If you answered "Yes" to question 14, please select any of the following changes that you may implement in your professional practice: (select all that apply)

3.

Linda Nayeli Morimoto, MD

4.

Single Select Question with enabled text for JA-2752

5.

Multi Select Question with enabled text for JA-2752

6.

Test Question 123